 Home > Encyclopedia > Sisomicin sulfate

Sisomicin sulfate

Sisomicin sulfate structure

CAS No:
53179-09-2
Formula:
C19H37N5O7.⁵/2H2O4S
Chemical Name:
Sisomicin sulfate
Synonyms:
D-Streptamine,O-3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-glycero-hex-4-enopyranosyl-(1→4)]-2-deoxy-,sulfate (2:5);D-Streptamine,O-3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-glycero-hex-4-enopyranosyl-(1→4)]-2-deoxy-,sulfate (2:5) (salt);Antibiotic 66-40 sulfate;Sisomicin sulfate;Sissomicin sulfate;Sisomycin sulfate;Sisolline;Baymicin;Mensiso;Sisobiotic;Sisomin;Extramycin;37281-43-9;70074-95-2
Categories:
Active Pharmaceutical Ingredients > Antibiotics

Description

Sisomicin sulfate is an aminoglycoside antibiotic.

Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).

Sisomicin sulfate Basic Attributes

Molecular Weight：

545.6

Exact Mass：

545.23667825 g/mol

EC Number：

258-414-4

DSSTox ID：

DTXSID9045479

HScode：

2941901010

Characteristics

PSA：

842.34000

XLogP3：

0.82120

Appearance：

white to off-white

Melting Point：

70-73C

Boiling Point：

155℃

Flash Point：

>110°(230°F)

Water Solubility：

H2O: soluble 50mg/mL

Storage Conditions：

2-8°C

Toxicity：

Subcutaneous-rat LD50: 500 mg/kg; peritoneal-mouse LD50: 221 mg/kg

Flammability characteristics：

Flammable; burning produces toxic nitrogen oxides and sulfur oxide fumes

Safety Information

Packing level：

Ⅲ

Transport codes：

2811

wgk germany：

hazard class code：

61-20/21/22-36/37/38

safety instructions：

53-22-36/37/39-45-36-26

RTECS Number：

WK2288000

Marks：

T,Xi

Storage features：

Treasury is ventilated, low temperature and dry; stored separately from food materials

Precautionary statement(s)：

P201-P261-P280-P308 + P313

Hazard Statements：

H312 + H332-H360

GHS Classification：

|Danger|H312 (97.5%): Harmful in contact with skin [Warning Acute toxicity, dermal]|P201, P202, P261, P271, P280, P281, P302+P352, P304+P312, P304+P340, P308+P313, P312, P322, P363, P405, and P501|Aggregated GHS information provided by 40 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

Toxicity class：

highly toxic

Drug Information

MeSH：

Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)|Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

MeSH Entry Terms：

4,5 Dehydrogentamicin

Sisomicin sulfate Use and Manufacturing

antibacterial, binds to ribosomes

Computed Properties

Molecular Weight:545.6
Hydrogen Bond Donor Count:10
Hydrogen Bond Acceptor Count:16
Rotatable Bond Count:6
Exact Mass:545.23667825
Monoisotopic Mass:545.23667825
Topological Polar Surface Area:297
Heavy Atom Count:36
Complexity:724
Defined Atom Stereocenter Count:11
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes

Material

Starch

Drug Function and Efficacy

Unspecified

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Sisomicin Sulfate and Sodium Chloride Injection
Specifications	100ml: contains 0.1g sisomicin (100,000 units) and 0.9g sodium chloride
Manufacturer	Jiangsu Yabang Shengyuan Pharmaceutical Co., Ltd.

Sisomicin sulfate
Manufacturer	Fujian Fukang Pharmaceutical Co., Ltd.

Sisomicin Sulfate Injection
Ingredients	Sisomicin sulfate.
Indication	1. This product can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects when used with other aminoglycosides or when applied topically or systemically one after the other. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product can aggravate neuromuscular blocking effects when used in combination with neuromuscular blocking drugs, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased, and hearing damage may occur, and may still progress to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product can increase nephrotoxicity when used topically or systemically with cephalothin. 4. This product should not be used in combination with polymyxins, or applied topically or systemically in sequence, because it can increase nephrotoxicity and neuromuscular blocking effects, the latter of which can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5. This product should not be used in combination with other nephrotoxic or ototoxic drugs or applied sequentially to avoid aggravating nephrotoxicity or ototoxicity. 6. This product should not be used in combination with amphotericin B, cephalothin sodium, nitrofurantoin sodium, sulfadiazine sodium and tetracycline (all of the above are injections) because of incompatibility. 7. This product can often achieve synergistic effects when used in combination with beta-lactams (cephalosporins or penicillins). 8. This product can be mixed with beta-lactams (cephalosporins or penicillins) to cause mutual inactivation. When used in combination, it must be dripped in separate bottles.
Specifications	1ml: 50,000 units

See More Related Drugs

Registered Holders

Fujian Fukang Pharmaceutical Co., Ltd.

China
Active
Wuxi Fortune Pharmaceutical Co., Ltd.

China
Active
Zhejiang Zhenyuan Pharmaceutical Co., Ltd.

China
Active

Recommended Suppliers of Sisomicin sulfate

Hangzhou Dawn Ray Pharmaceutical Co.,Ltd Contact Supplier

CN
5 YRS

Business licensed Certified factory

Manufactory Supplier of D-Biotin,Tobramycin base,L(-)-Carnitine base,Polymyxin B sulfate USP,Kanamycin sulfate monohydrate,Finasteride 99% USP

sisomicin sulfate USP API >=98.0% made in china

CAS No.: 53179-09-2

Inquiry
HANGZHOU LEAP CHEM CO., LTD. Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives

Sisomicin sulfate

CAS No.: 53179-09-2

Content: 99.00%

Inquiry